Contraceptive Hormones, Immunity, and Microbiome Evaluation

Completed

• Conditions: Hormonal Contraception
• Interventions: Drug: Etonogestrel implant (Eng-Implant); Drug: Depot medroxyprogesterone acetate (DMPA); Drug: Levonorgestrel IUD (Lng-IUD)

• Registration Number: NCT03660046
• Lead Sponsor: Emory University

Brief Summary

The study is a prospective cohort study to explore the mechanisms underlying the HIV risk associated with pharmacologic doses of exogenous sex hormones via hormonal contraceptives specially progestin-containing hormonal contraception (HC). The study seeks to test that HC induce immunologic changes capable of altering HIV susceptibilities, that these effects will vary by contraceptive type, and that they will be modified by the vaginal microenvironment.

Detailed Description

This study is a translational research project to explore the mechanisms underlying the HIV risk associated with pharmacologic doses of exogenous sex hormones (via hormonal contraceptives). Emerging data suggests that certain hormonal contraceptives may induce mucosal and systemic immune changes that could increase the risk of infection with HIV. While several studies have aimed to characterize immunologic changes in women using hormonal contraceptives, the nature and the magnitude of these immune changes have not been adequately defined due to limitations in study design rigor, and small and statistically underpowered sample sizes.

The study will prospectively recruit cohorts of HIV-uninfected women initiating hormonal contraception to characterize systemic and lower genital tract innate and adaptive immunologic changes that occur over a course of up to 4 months. This study will test the overarching hypothesis that hormonal contraceptives induce systemic and mucosal immune changes capable of altering susceptibilities and/or responses to diseases including HIV infection, and that these effects vary markedly in nature and magnitude by contraceptive type and will be modified by the vaginal microenvironment. The main aim is to determine the immunologic alterations in female genital and systemic immune profile associated with depot medroxyprogesterone acetate (DMPA), Etonogestrel implant (Eng-Implant) and Levonorgestrel IUD (Lng-IUD).

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2018-09-04
• Study First Submitted QC: 2018-09-04
• Study First Posted: 2018-09-06
• Study Start: 2018-12-07
• Primary Completion: 2023-09-07
• Study Completion: 2023-09-07
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-25
• Last Update Posted: 2024-10-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 155

Inclusion Criteria

• Female sex, defined by sex at birth.
• Age ≤ 45 years. If < 18 years of age, participant must be capable of providing assent, understanding and complying with all study procedures, and have written informed consent from a parent or legal guardian.
• Normal menses (occurring within 22-35 day intervals) for > 2 cycles. Women who are postpartum or post-abortion who have resumed menses are eligible.
• Intact uterus and cervix.
• Interested in initiating HC and willing to accept DMPA, Eng-Implant or Lng-IUD.
• Willing to delay initiation of HC for up to 1 month.
• Able and willing to provide informed consent, and undergo study procedures.
• Negative HIV test by Ora-Quick© method at Screening Visit.
• Agree to abstain from vaginal intercourse or using intra-vaginal products for 1 day prior to each study visit.

Read More

Exclusion Criteria

• Pregnant or planning to become pregnant within the next year.
• Breastfeeding, if not having active menstrual cycles. Breastfeeding is not exclusionary if the participant is actively cycling.
• History of loop electrosurgical excision procedure (LEEP), conization, or cryosurgery within the past year.
• Current use of systemic HC or IUD, based on self-report and/or hormonal testing.
• Taking concurrent medications that interact with selected HC.
• Contraindications to selected contraceptive per the Center for Disease Control medical eligibility criteria or judgment of clinician.
• Allergy to lidocaine for cervical biopsies (if consenting to optional biopsies).

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Etonogestrel implant (Eng-Implant)	Etonogestrel implant (Eng-Implant)	This arm includes subjects that choose Etonogestrel implant (Eng-Implant) as contraception.
Depot medroxyprogesterone acetate (DMPA)	Depot medroxyprogesterone acetate (DMPA)	This arm includes subjects that choose Depot medroxyprogesterone acetate (DMPA) as contraception.
Levonorgestrel IUD (Lng-IUD)	Levonorgestrel IUD (Lng-IUD)	This arm includes subjects that choose Levonorgestrel Intrauterine device (Lng-IUD) as contraception.

Primary Outcome Measures

Name	Time	Method
Change in mean total leukocytes and CD4+ T-cells expressing CCR5 in the lower female genital tract (FGT) among the three intervention groups pre and post contraception	Week 1 and Week 3 (pre contraception), and 13 and 15 weeks after initiating contraception	Using Fortessa flow cytometer and Luminex, effector memory Cluster Differentiation 4 (CD4) + Thymocytes (T) cells will be analyzed for surface expression of HIV coreceptors cell surface receptor C-C chemokine receptor type 5 (CCR5) and reported as percent of total leukocytes and CD4+ T-cells. The cytometry will use the cervicovaginal fluid (CVF) collected by cervicovaginal lavage (CVL).This test will characterize the alterations in female genital and systemic immune profiles associated with three long-acting progestin-only Hormonal Contraception.
Change in Nugent's score among the three intervention groups pre and post contraception	Week 1 and Week 3 (pre contraception), and 13 and 15 weeks after initiating contraception	The Nugent Score is a Gram stain scoring system for vaginal swabs to diagnose bacterial vaginosis. The Nugent score is calculated by assessing for the presence of large Gram-positive rods (Lactobacillus morphotypes; decrease in Lactobacillus scored as 0 to 4), small Gram-variable rods (Gardnerella vaginalis morphotypes; scored as 0 to 4), and curved Gram-variable rods (Mobiluncus spp. morphotypes; scored as 0 to 2). A score of 7 to 10 is consistent with bacterial vaginosis without culture.
Percent of expression of 16S rRNA gene sequencing among the three intervention groups pre and post contraception	Week 1 and Week 3 (pre contraception), and 13 and 15 weeks after initiating contraception	16 Svedberg ribosomal RNA (16S rRNA) is the component of the 30 Svedberg ribosomal RNA (30S rRNA) small subunit of a prokaryotic ribosome that binds to the Shine-Dalgarno sequence. The genes coding for it are referred to as 16S rRNA gene and are used in reconstructing phylogenies. 16S rRNA gene sequence analysis can better identify poorly described, rarely isolated, or phenotypically aberrant strains, can be routinely used for identification of mycobacteria, and can lead to the recognition of novel pathogens and uncultured bacteria.The term 16S refers to how it settles to when centrifuged (it's called a sedimentation rate, and it's measured in Svedberg (S) units).

Trial Locations

Locations (3)

Grady Health System; 🇺🇸 Atlanta, Georgia, United States

The Emory Clinic, Bldg A., 2nd Floor, 1365 Clifton Road, NE; 🇺🇸 Atlanta, Georgia, United States

Atlanta Women's Center; 🇺🇸 Atlanta, Georgia, United States